Beta-blockers before coronary artery bypass grafting surgery not associated with better outcomes

June 16, 2014

Use of beta (β)-blockers in patients who have not had a recent heart attack but were undergoing nonemergency coronary artery bypass grafting (CABG) surgery was not associated with better outcomes.

The use of preoperative β-blockers has been associated with a reduction in perioperative mortality for patients undergoing CABG in previous observational studies. Preoperative β-blocker therapy is a national quality standard.

The authors conducted a retrospective analysis of the Society of Thoracic Surgeons National Adult Cardiac database of U.S. hospitals performing from 2008 to 2012. The study included 506,110 patients undergoing nonemergency CABG surgery who had not had a heart attack in the previous 21 days or any other high-risk symptoms.

Of the 506,110 patients, 86.2 percent received preoperative β-blockers within 24 hours of surgery. The authors found no difference between patients who did and did not receive preoperative β-blockers in rates of death due to the operation, stroke, prolonged ventilation, any reoperation, renal failure and deep sternal wound infection. Patients who received preoperative β-blockers did have higher rates of new-onset atrial fibrillation than patients who did not.

"β-blockers are an important and effective tool in the care of patients undergoing cardiac surgery in specific clinical scenarios. However, the empirical use of β-blockers as recommended by the National Quality Forum (without physiologic goals i.e., adequate clinical drug levels) in all before CABG may not improve outcomes. A with careful attention to adequate dosing and specific drug type may help to answer this question," William Brinkman, M.D., of the Cardiopulmonary Research Science and Technology Institute, Dallas, and colleagues said in their JAMA Internal Medicine article.

Explore further: Beta-blockers before surgery appear associated with lower risk of heart-related events

More information: JAMA Intern Med. Published online June 16, 2014. DOI: 10.1001/jamainternmed.2014.2356
JAMA Intern Med. Published online June 16, 2014. DOI: 10.1001/jamainternmed.2014.155

Related Stories

Beta-blockers have no impact on cocaine-related chest pain

June 3, 2014

(HealthDay)—For patients with cocaine-associated chest pain, there are no differences in outcome for those treated with or without β-blockers, according to a study published in the June 1 issue of The American Journal ...

Post-op kidney risk reduced in 'off-pump' patients

June 4, 2014

(Medical Xpress)—Among patients undergoing coronary artery bypass graft (CABG) surgery, those who were not put on a heart-lung machine (off-pump) had a reduced risk of postoperative kidney injury compared to patients who ...

Recommended for you

Researchers find sleep gene linked to heart failure

November 30, 2015

Researchers at the Stanford University School of Medicine have identified a gene that, when working properly, appears to reduce the risk of heart failure and improve treatment outcomes, highlighting a possible target for ...

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.